|
|
 |
|
Viewing report
|
|
|
|
Cardiovascular Biomarkers: Players, Products and Prospects (Volume III)
Espicom Business Intelligence Ltd, Aug 2008, Pages: 120
Part of our new 3-volume report on Cancer, CNS and Cardiovascular Biomarkers, this volume provides a comprehensive analysis of the cardiovascular biomarker sector, along with a critical assessment of the companies involved.
In 2007, the cardiovascular biomarker market accounted for an estimated 23% of biomarker revenues to generate over US$1.3 billion with the majority of revenues derived from biomarker discovery and molecular diagnostics. The market has yet to reach the maturity of the oncology biomarker market, but over the coming years the importance of genetic markers and companion diagnostics will grow. By 2015, the estimated market value will be US$6.6 billion, with biomarker discovery being the largest component.
One of the largest markets for cardiovascular biomarkers lies in the diagnosis of acute coronary syndromes in patients presenting with acute signs and symptoms, such as shortness of breath or chest pain.
For example, Troponin is well established as a diagnostic marker of myocardial infarction and has been described as the cornerstone of diagnosis for the condition. However, the marker has a major limitation: troponin levels only rise six to eight hours after a myocardial ischaemia. The search for new diagnostic biomarkers for use in the acute setting has focused on the identification of earlier markers of infarction. These include ischaemia modified albumin (IMA) as well as potential markers, heart fatty acid binding protein and glycogen phosphorylase isoenzyme BB (GPBB). In addition, some of the leading providers are suggesting that panels of cardiac markers are most useful for diagnosis in acute settings. Examples include Biosite’s (now part of Inverness Medical Innovations) CardioProfiler Triage panel. This is a PoC diagnostic that measures a number of markers including Troponin I, CK-MB, myoglobin and BNP. New multi-marker panels are also under development. These include an index score panel for the diagnosis of peripheral artery disease (VASCLIR, Vermillion). The panel evaluates ß-2-microglobulin, cystatin C, hsCRP and glucose to create an index score and is currently in clinical trials.
Screening patients for prediction of future cardiovascular disease is currently the second major market for cardiovascular biomarkers. These markers include lipid biomarkers (e.g. LDL, HDL, triglycerides, LDL particle number and lipoprotein concentrations) or inflammatory biomarkers (e.g. CRP or Lp-PLA2). Lipid profiles are well-established as indicators of future cardiovascular risk that can be reduced through the use of lipid-lowering therapies such as statins.
Questions, Questions
- What clinical studies are CardioDx currently engaged in?
- What approach is deCODE Genetics taking in its research?
- Which pharmaceutical companies are utilising Entelos predictive biostimulation technology?
Focus on...market potential
In 2007, the cardiovascular biomarker market accounted for and estimated 23% of biomarker revenues generating over US$1.3 billion, with the majority of revenues derived from biomarker discovery and molecular diagnostics. The market has yet to reach the maturity of the oncology biomarker market, but will grow in the short term with the introduction of new, proprietary markers for acute coronary syndromes. Over the coming years, the importance of genetic markers and companion diagnostics will grow.
By 2015, we estimate the global cardiovascular biomarker market will account for around one third of global biomarker sales and will be worth up to US$6.6 billion as it becomes more mature; driven by growth in clinical biomarkers, the development of targeted therapies and associated companion diagnostics, discovery and validation of genetic markers of cardiovascular risk and reimbursement of pharmacogenomic and prognostic tests.
Also available
Cancer, CNS & Cardiovascular Biomarkers: Players, Products and Prospects
Cancer Biomarkers: Players, Products and Prospects (Volume I)
CNS Biomarkers: Players, Products and Prospects (Volume II)
Customers who bought this item also bought
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Blood Biomarkers and Beyond: Biomarker and Diagnostic Opportunities in Cardiovascular Disease
Cancer, CNS & Cardiovascular Biomarkers: Players, Products and Prospects
Licensing Strategies for Accessing Biomarker Technologies
Biomarker and Diagnostic Opportunities in Clinical Research for Neurological Diseases
It's All About the Biomarkers: How 2008's Biomarker-Based Partnering Is Driving Personalized Medicine
Clinical Proteomics: Rethinking Approaches to Protein Biomarker Discovery
How Overcoming the Challenge of Biomarker Validation Can Pay Off for Drug and Diagnostic Developers
Harnessing Biomarker Research in Academic Institutions for Use in Industry
Cancer Biomarkers: Players, Products and Prospects (Volume I)
CNS Biomarkers: Players, Products and Prospects (Volume II)
Biomarkers - Technologies, Markets and Companies
|
|
|
|
